Merck KGaA said 25 cancer-study abstracts were accepted for ESMO 2026, including planned safety and survival data. The announcement gives no study findings, so it does not show a change in the company's outlook.
The company is sharing study updates, but this story does not say whether either treatment worked or caused safety problems. That makes this a research update, not a change in what the evidence shows about Merck KGaA's cancer medicines.
Follow Merck KGaA (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK